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Diffuse cutaneous leishmaniasis (DCL) is a rare clinical manifestation of tegumentary leishmaniasis. The mo-
lecular mechanisms underlying DCL pathogenesis remain unclear, and there is no efficient treatment available.
This study investigated the systemic and in situ expression of the inflammatory response that might contribute
to suppression in DCL. The plasma levels of arginase I, ornithine decarboxylase (ODC), transforming growth
factor β (TGF-β), and prostaglandin E2 (PGE2) were higher in patients with DCL, compared with patients with
localized cutaneous leishmaniasis (LCL) or with controls from an area of endemicity. In situ transcriptomic
analyses reinforced the association between arginase I expression and enzymes involved in prostaglandin and
polyamine synthesis. Immunohistochemistry confirmed that arginase I, ODC, and cyclooxygenase2 expression
was higher in lesion biopsy specimens from patients with DCL than in those from patients with LCL. Inhibition
of arginase I or ODC abrogates L. amazonensis replication in infected human macrophages. Our data implicate
arginase I, ODC, PGE2, and TGF-β in the failure to mount an efficient immune response and suggest perspec-
tives in the development of new strategies for therapeutic intervention for patients with DCL.
Keywords. Leishmania amazonensis; diffuse cutaneous leishmaniasis; arginase I; ornithine decarboxylase; pros-
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Cutaneous leishmaniasis exhibits a wide spectrum of
clinical manifestations varying from self-healing local-
ized cutaneous leishmaniasis (LCL) with a moderate
cell-mediated immune response to diffuse cutaneous
leishmaniasis (DCL) [1]. DCL is distinct from dissemi-
nated cutaneous leishmaniasis [2] and is characterized
by the presence of several nonulcerated nodular skin le-
sions, the predominance of highly parasitized macro-
phages in the lesions, an absent or modest in vitro
antileishmanial antigen cellular immune response, a
negative delayed-type hypersensitivity (DTH) response,
and resistance to antiparasite therapy [3]. The molecu-
lar mechanisms underlying DCL pathogenesis remain
unclear, and there is no efficient treatment available.
In patients with DCL, antiinflammatory cytokines
are abundant in lesions and in restimulated peripheral
blood mononuclear cells (PBMCs), whereas proinflam-
matory cytokines and chemokines are absent or present
at low levels [1]. However, the mechanisms responsible
for this imbalance are not yet understood.
The arginase I pathway is emerging as a critical mech-
anism of immune regulation in Leishmania infection [4]
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and is highly expressed in lesions from patients with LCL [5].
This enzyme metabolizes L-arginine into urea and L-ornithine,
the substrate used for ornithine decarboxylase (ODC) to
produce polyamines that are crucial for parasite replication.
Macrophages infected with Leishmania major or Leishmania
infantum and treated with LOHA (L-hydroxyl arginine), an
arginase inhibitor, exhibit significant decrease in parasite load
[6].Moreover, DFMO, a potent ODC inhibitor, effectively inhi-
bits Leishmania donovani promastigote growth in culture [7].
Leishmania amazonensis, the sole agent implicated in DCL in
Brazil [8], increases arginase I, transforming growth factor β
(TGF-β), and prostaglandin E2 (PGE2) expression, contributing
to intra-macrophage parasite proliferation [9–11].Nevertheless,
the relevance of these mediators in DCL pathogenesis remains
unknown. In the present study, we investigated the systemic lev-
els and in situ expression of inflammatory mediators in samples
from patients with DCL, patients with LCL, and healthy con-
trols, who were identified among family members of patients
with DCL. High levels of arginase I, ODC, PGE2, and TGF-β
were observed in plasma specimens from patients with DCL.
In addition, in situ transcriptomic analyses reinforced the asso-
ciation between arginase I expression and the enzymes involved
in the pathways of prostaglandin and polyamine biosynthesis at
the messenger RNA (mRNA) level. Moreover, arginase and
ODC inhibitors prevented parasite replication and modulated
inflammatory mediators in human monocyte-derived macro-
phages infected with L. amazonensis. Our study highlights
that arginase I, ODC, and COX-2 biosynthetic enzymes can
be used as potential drug targets for Leishmania infection.
MATERIALS AND METHODS
Ethics Statement
Written informed consent was obtained from all participants
or legal guardians, and all data analyzed were anonymized.
The project was approved by the institutional review board of
Centro de Pesquisas Gonçalo Moniz, FIOCRUZ–BA (license
number 136/2007), and comply with the guidelines of the Dec-
laration of Helsinki.
Patient Characteristics
All patients with DCL (n = 12) were followed by one of the au-
thors (J. M. C.), and their characteristics have been reported
previously [3]. Their diagnoses were established as described
elsewhere [12]. Patients with DCL exhibited a chronic evolution
of the disease with several remissions, multiple nodular and
highly parasitized lesions throughout the skin, and a negative
DTH response. Patients with LCL (n = 29) with a single or
few ulcerated lesions present for up to 2 months and a positive
DTH response were followed by one of the authors (A. B.) [13].
The clinical and epidemiological data from patients with DCL
and those with LCL are summarized in Table 1. Controls were
identified among 49 family members of the patients with DCL
and underwent careful physical examinations, exhibiting no
cutaneous lesions or prior CL history and a negative DTH re-
sponse. Individual blood samples were collected after examina-
tion. Skin biopsy specimens (3 or 4 mm) were obtained from 4
patients with DCL and 7 patients with LCL, embedded in a
cryopreservation resin, snap frozen, and stored in liquid nitro-
gen. We did not have lesion biopsy specimens available from all
patients during the period of this study, and since the procedure
is too invasive not all patients have allowed collection of a new
lesion biopsy specimen.
Inflammatory Mediator Measurements
Plasma levels of arginase I (Hycult Biotech, Uden, the Nether-
lands), ODC (Wuhan EIAAB Science, Wuhan, China) and
TGF-β (R&D Systems, Minneapolis, Minnesota) were measured
using enzyme-linked immunosorbent assay ELISA according to
the manufacturer’s instructions. The total TGF-β level was mea-
sured in plasma after acidification, according to the manufac-
turer’s instructions. The plasma levels of interleukin 10
(IL-10), interleukin 12 (IL-12), interferon γ (IFN-γ), monocyte
chemotactic protein 1 (MCP-1), CXCL-10, and tumor necrosis
factor α (TNF-α) were measured using a Cytometric Bead
Array (CBA) Human Inflammatory kit (BD Biosciences Phar-
mingen, San Diego, California) according to the manufacturer’s
protocol. The flow cytometry assay was performed and analyzed
by a single operator. PGE2 production wasmeasured using a spe-
cific enzyme immunoassay (the PGE2 EIA kit, Cayman Chemi-
cal, Ann Arbor, Michigan) according to the manufacturer’s
instructions. TGF-β, PGE2, TNF-α, and IL-12 expression was
measured in supernatants by the same protocols.
Table 1. Epidemiological and Clinical Parameters for Patients
With Diffuse Cutaneous Leishmaniasis (DCL) and Those With
Localized Cutaneous Leishmaniasis (LCL)
Characteristic
LCL Group
(n = 29)
DCL Group
(n = 12)
P
value
Sex, no. .09
Male 19 7
Female 10 5
Age, y .06
Mean ± SD 34 ± 15 17 ± 23
Range 13–65 4–41
Active lesions, no. .001
Mean 1 138
Range 1–9 22–500
DTH positivity, % 100 0 .0001
Disease duration, mo .0001
Mean 3 142
Range 1–6 36–276
Abbreviations: DTH, delayed hypersensitivity skin-test response; SD, standard
deviation.
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Measurement of Arginase Enzymatic Activity
Arginase activity wasmeasured by a colorimetric assay for the de-
tection of urea in plasma samples, as previously described [14].
Immunohistochemistry
Immunohistochemistry was performed as previously reported by
us [15], using primary antibodies against human arginase I (2 µg/
mL; 1:100; Santa Cruz Biotechnology, Dallas, Texas), ODC (4 µg/
mL; 1:100; Cayman Chemical, Ann Arbor, Michigan), and COX-2
(2 µg/mL; 1:50; Cayman Chemical, Ann Arbor, Michigan). Digital
images were obtained from fields of 400× original magnification
and captured using a Nikon E600 microscope and an Olympus
Q-Color 1 digital camera with the Image-Pro Plus program.
nCounter Analysis
Total RNA was extracted from lesion biopsy specimens from 4
patients with DCL and 7 patients with LCL, using TRIzol,
according to the manufacturer’s protocol, with an additional
purification step performed using RNeasy columns (Qiagen
Benelux, Venlo, the Netherlands). nCounter (NanoString Tech-
nologies, Seattle, Washington) analysis was performed at the
VIB MicroArray Facility (Leuven, Belgium) based on direct mo-
lecular bar coding of target RNA transcripts and digital detec-
tion [16]. Through the use of color-coded probe pairs and direct
hybridization and without the use of reverse transcriptase
or amplification, the following host-specific cellular genes
were quantified: ARGI, which encodes arginase I; ODC, which
encodes ornithine decarboxylase; EP1, which encodes prostaglan-
din E receptor 1; EP2, which encodes prostaglandin E receptor 2;
EP3, which encodes prostaglandin E receptor 3; EP4, which en-
codes prostaglandin E receptor 4; PLA2G4A, which encodes
phospholipase A2, group IVA (cytosolic, calcium-dependent);
PTGS1, which encodes prostaglandin-endoperoxide synthase 1;
PTGS2, which encodes prostaglandin-endoperoxide synthase 2;
PTGES, which encodes prostaglandin E synthase; SMS, which
encodes spermine synthase; and SRM, which encodes spermi-
dine synthase. The following housekeeping genes were also
quantified for normalization at the femtomolar range: GUSB,
Figure 1. Arginase I, ornithine decarboxylase (ODC), and antiinflammatory mediators in plasma specimens from patients with diffuse cutaneous leish-
maniasis (DCL) and those with localized cutaneous leishmaniasis (LCL). Plasma protein levels of arginase I (A), ODC (B), transforming growth factor β (TGF-β;
C), and prostaglandin E2 (PGE2; D) were measured by an enzyme-linked immunosorbent assay in healthy controls (n = 35), patients with active DCL (n = 12),
and patients with localized cutaneous leishmaniasis (LCL; n = 30). Correlations between arginase I and arginase activity (E ), ODC (F ), TGF-β (G), and PGE2 (H)
were calculated. Each point represents a different donor, and each bar represents the median. Open circles represent patients with DCL, and closed circles
represent patients with LCL. Differences between groups were tested by the Kruskal–Wallis test with the Dunn multiple comparisons post hoc test. The
Spearman test was used to verify the significance of correlations between parameters. Data are representative of at least 2 independent assays performed
in duplicate for each patient or control.
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which encodes β-glucuronidase; G6PD, which encodes glucose-
6-phosphate dehydrogenase; GAPDH, which encodes glyceral-
dehyde-3-phosphate dehydrogenase; HPRT1, which encodes
hypoxanthine phosphoribosyltransferase; and CD45, which en-
codes the pan-leukocyte marker CD45.
Cell Culture
PBMCs and monocytes were isolated and cultured as previously
described [17]. The promastigotes used in these experiments
came from an L. amazonensis strain (MHOM/BR/87/BA336) iso-
lated from a patient with DCL. The methods of parasite culture
and macrophage infection have been previously reported [18].
Macrophages were infected with early stationary phase L. amazo-
nensis at a parasite to cell ratio of 6:1. After 4 hours of incubation
at 34°C, free parasites were removed by extensive washing with
phosphate-buffered saline, and 10 µg/mL nor-NOHA or 0.5
mMDFMO (arginase and ODC inhibitors) was added to the cul-
tures (both from Sigma-Aldrich, St. Louis, Missouri). The intra-
cellular parasite load was estimated at 24 and 72 hours after
infection by light microscopy and the production of viable pro-
mastigotes in Schneider medium, as described previously [18].
Statistical Analysis
For ordinal variables, differences between groups were cal-
culated using the nonparametric Kruskal–Wallis test with
the 2-tailed Dunn multiple comparisons post hoc test and the
Mann–Whitney unpaired t test for 2-group comparisons. The
χ2 test was used to compare differences between categorical var-
iables. The Spearman test was used to verify the significance of
correlations between arginase I and the plasma levels of argi-
nase activity, ODC, TGF-β, PGE2, TNF-α, IL-12, MCP-1,
IFN-γ, and CXCL-10 (nonparametric data). For transcriptomic
Figure 2. Proinflammatory cytokines and chemokines in plasma specimens from patients with diffuse cutaneous leishmaniasis (DCL) and those with
localized cutaneous leishmaniasis (LCL). Plasma protein levels of tumor necrosis factor α (TNF-α; A), interleukin 12 (IL-12; B), monocyte chemotactic protein
1 (MCP-1; C), and CXCL-10 (D) were measured by the Cytometric Bead Array kit in healthy controls (n = 35), patients with active DCL (n = 12), and patients
with LCL (n = 30). Correlations between arginase I and TNF-α (E ), IL-12 (F ), MCP-1 (G), and CXCL-10 (H) levels were measured. Each point represents a
different individual, and each bar represents the median. Open circles represent patients with DCL, and closed circles represent LCL patients. Differences
between groups were tested by the Kruskal–Wallis test with the Dunn multiple comparisons post hoc test. The Spearman test was used to verify the
significance of correlations between parameters. Data are representative from at least 2 independent assays performed in duplicate for each patient or
control.
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(nCounter) analysis, in situ mRNA levels were normalized to
CD45 mRNA levels, followed by log transformation, allowing
linear regression analysis of the interactions between inflamma-
torymediators, as previously described [19,20]. The values in the
text represent medians ± standard deviations. Differences were
considered statistically significant at P values of ≤ .05. Data
were analyzed using GraphPad Prism 5.0 (GraphPad Software).
RESULTS
Inflammatory Imbalance Mediators in Plasma
Specimens From Patients With DCL
Plasma specimens from patients with DCL exhibited the highest
arginase I levels, by at least 5-fold, compared with patients with
LCL or controls (Figure 1A). Patients with DCL also exhibited
higher arginase activity (69.850 ± 29.017 U/mL) than patientswith
LCL (36.602 ± 9.659 U/mL) and controls (28.971 ± 11.037
U/mL). L-Ornithine, the arginase product, can be used by
ODC, resulting in polyamine production [14]. ODC was aug-
mented in DCL plasma when compared with the control and
LCL groups (Figure 1B).
We next investigated the mediators known to modulate the
L-arginine metabolic pathways. TGF-β displayed higher levels
in plasma from patients with DCL than patients with LCL (Fig-
ure 1C). Similarly, PGE2 levels were higher in patients with DCL
than in controls, but no difference was detected between pa-
tients with DCL and patients with LCL (Figure 1D). Arginase
I exhibited a positive correlation with antiinflammatory media-
tors, including arginase activity, ODC, TGF-β, and PGE2 (Fig-
ure 1E–H). However, the proinflammatory cytokines and
chemokines TNF-α (Figure 2A), IL-12 (Figure 2B), MCP-1
(Figure 2C), and CXCL-10 (Figure 2D) were reduced in plasma
specimens from the DCL group, compared with levels in plasma
from the LCL and control groups. Arginase I exhibited a nega-
tive correlation with TNF-α, IL-12, and CXCL-10 (Figure 2E–
H) but not with MCP-1 (Figure 2G).
To determine whether arginase I, ODC, and COX-2 were also
expressed in situ, we performed a comprehensive analysis of
genes implicated in this inflammatory pathways. The mRNA
levels of the selected genes were quantified and normalized to
the mRNA level of the pan-leukocyte marker CD45 to correct
varying levels of leukocyte infiltration between patient lesion bi-
opsy specimens. Cells in lesion biopsy specimens from the DCL
group exhibited significantly increased arginase I mRNA levels,
compared with those from the LCL group (Table 2), corroborat-
ing the increased levels of this enzyme found in plasma speci-
mens from patients with DCL. However, the ODCmRNA levels
did not significantly differ between the DCL and LCL groups.
The mRNA levels of IL-4 and IL-10 were significantly increased,
although the TNF-αmRNA level was decreased in lesions from
the DCL group in situ (Table 2). PGE2 binds to 4 cellular recep-
tors, of which EP2 mRNA was significantly overexpressed in
lesion biopsy specimens from the DCL group, compared with
those from the LCL group (Table 2). Present upstream of
PGE2, phospholipase A2 is the crucial enzyme for arachidonic
acid production, and levels of this enzyme were significantly
higher in DCL lesions, compared with LCL lesions (Table 2).
As shown in Figure. 3, arginase I mRNA levels were positively
correlated with PLA2G4A, PTGES, and PTGS2 mRNA levels
(Figure 3A–C), all of which are enzymes involved in prostaglan-
din synthesis. Arginase I expression was also positively correlat-
ed with spermine synthase and spermidine synthase expression
(Figure 3D and 3E ), which are enzymes responsible for poly-
amine synthesis.
Arginase I, ODC, and COX-2 Expression in Lesion Biopsy
Specimens From Patients With DCL
Arginase I staining was more widespread in lesion biopsy spec-
imens from the DCL group (n = 3) than in those from the LCL
group (n = 3), as shown in Figure 4. The expression of ODC and
COX-2, which are involved in polyamine and PGE2 synthesis,
respectively, exhibited an increase in DCL lesions when com-
pared with LCL lesions. No reactivity was detected using an iso-
type control antibody (data not shown).
Arginase and ODC Inhibition Control L. amazonensis
Infection in Human Macrophages
Macrophages infected with Leishmania organisms exhibited
10.9 × 104 ± 2.1 × 104 viable parasites at 24 hours after infection.
The groups treated with nor-NOHA or DFMO presented no
difference in parasite load at the same time (Figure 5A). How-
ever, 72 hours after infection, the unstimulated cells group
showed parasite proliferation (6.2 × 107 ± 1.75 × 107), and the
groups treated with nor-NOHA and DFMO exhibited 3.6 × 104 ±
6.05 × 104 and 1 × 105 ± 1.40 × 104 viable parasites, respectively,
Table 2. Messenger RNA (mRNA) Levels of Inflammatory
Mediators in Lesion Biopsy Specimens From Patients With
Diffuse Cutaneous Leishmaniasis (DCL) and Those With
Localized Cutaneous Leishmaniasis (LCL)
Mediator LCL Group (n = 7) DCL Group (n = 4) P value
Arginase I 0.02 1.02 <.04
ODC −0.63 −0.88 <.64
EP-2 −0.96 −0.53 <.006
PLA2G4A −1.28 −1.02 <.09
Interleukin 4 −3.02 −1.72 <.02
Interleukin 10 −2.47 1.66 <.01
TNF-α −0.35 −0.68 <.01
Values were obtained by nCounter digital quantification of mRNA levels and
normalized to the CD45 mRNA level, followed by log transformation.
Negative values thus reflect a ratio of mediator mRNA level to CD45 mRNA
level of <1.
Abbreviations: EP-2, prostaglandin E receptor 2; ODC, ornithine decarboxylase;
PLA2G4A, phospholipase A2, group IVA; TNF-α, tumor necrosis factor α.
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which were both significantly lower than the level in unstimu-
lated cells (Figure 5A). In addition, at 72 hours after infection,
photomicrographs confirmed that cells treated with nor-
NOHA and DFMO were able to control the parasite burden
more efficiently than cells in the untreated group (Figure 5B).
Next, we measured essential mediators of L. amazonensis
survival and proliferation in human macrophage culture super-
natants at 24 hours. First, we observed that nor-NOHA or
DFMO treatment decreased TGF-β (Figure 5C) and PGE2 (Fig-
ure 5D) production by at least 50%, compared with the control
group. Subsequently, we measured the levels of key cytokines
that control Leishmania infection. nor-NOHA–treated cells ex-
hibited a 3-fold increase in both TNF-α (Figure 5E ) and IL-12
(Figure 5F) levels, whereas DFMO-treated cells did not exhibit
altered cytokine levels, compared with untreated cells.
DISCUSSION
DCL is characterized by an inefficient parasite-specific cellular
response and heavily parasitized macrophages. However, the
immunopathogenic mechanisms underlying this disease re-
main unclear. The findings reported here lead us to propose a
straightforward pathway by which arginase I, ODC, PGE2, and
TGF-β contribute to DCL lesions, thus resulting in a permissive
microenvironment for Leishmania proliferation and progres-
sion to chronic disease.
Plasma from patients with DCL exhibited higher levels of ar-
ginase I expression and activity, compared with plasma from
patients with LCL or controls. High levels of arginase activity
in plasma and saliva have been reported in several other
human pathologic conditions as a useful biological biomarker,
Figure 3. Arginase I in situ is related to polyamine and PG pathways in lesion biopsy specimens from patients with diffuse cutaneous leishmaniasis (DCL)
and those with localized cutaneous leishmaniasis (LCL). Total RNAwas extracted from lesion biopsy specimens for patients with LCL (n = 7) and those with
DCL (n = 4), and the messenger RNA transcripts of host-specific cellular genes were quantified by nCounter (Nanostring), including that of a housekeeping
gene encoding CD45, for normalization. Linear regression between ARG1 (which encodes arginase I) and PLA2G4A (which encodes phospholipase A2; (A),
PTGES (which encodes prostaglandin E synthase; (B), PTGS2 (which encodes prostaglandin-endoperoxide synthase [known as cyclooxygenase 2]; (C), and
the polyamine biosynthetic pathways for SMS (which encodes spermine synthase; (D) and SMR (which encodes spermidine synthase; (E ). Open circles
represent patients with DCL, and closed circles represent patients with LCL. The statistical significance of differences was determined by linear regression.
The data were collected in triplicate for each donor.
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in some cases representing an indicator of disease progression
[21, 22], but the mechanism by which arginase I is released re-
mains unclear. Recently, increased arginase I activity was dem-
onstrated in situ in LCL lesions from Ethiopian patients [5], as
well as in plasma specimens from patients with visceral leish-
maniasis [14]. The difference in arginase I expression in plasma
and lesions could be due to parasite-related factors or could be a
consequence of polymorphisms in host genes, as indicated for
other pathologic conditions [23, 24]. Regardless of arginase I
source, the data presented here suggest that arginase I levels
in plasma are unbalanced in patients with DCL and those
with LCL, compared with healthy controls. Furthermore, the re-
lationship between arginase I levels and clinical presentations
suggests that arginase I may represent a biomarker for cutane-
ous leishmaniasis severity.
The arginase I pathway is preferentially driven by the pres-
ence of antiinflammatory mediators, such as the lipid mediator
PGE2 [25] and TGF-β [26]. Although PGE2 production in plas-
ma specimens from patients with DCL and those with LCL did
not differ, both patient subgroups exhibited higher values, com-
pared with values for controls, indicating that PGE2 might
be relevant to cutaneous leishmaniasis. PGE2 can use 4 G-
protein–coupled E-prostanoid receptors (prostaglandin E re-
ceptors 1–4) [27]. Interestingly, differences between DCL and
LCL lesions were only detected in EP2 mRNA levels. PGE2 sig-
naling through EP2 promotes T-helper type 2 (Th2) immune
responses [28] and the suppression of the microbicidal activity
of alveolar macrophages through prostaglandin E receptors 2/4,
increasing cAMP levels and inhibiting the assembly and activa-
tion of p47phox [29].
Indeed, the potent immunomodulatory effects exhibited by
PGE2 are ambiguous, depending on the profile of in situ medi-
ators. PGE2 has been shown to synergize with TNF-α to induce
high levels of IL-12 production by dendritic cells [30], whereas
TGF-β synergizes with PGE2 to block IFN-γ and TNF-α secre-
tion [31]. These effects are associated with suppression of the
host immune response and a switch from a Th1 to a Th2 re-
sponse [32]. Therefore, systemic PGE2 in LCL, in concert
with TNF-α and IL-12, appears to support effective activation
of the immune system, whereas in patients with DCL, PGE2
and TGF-β have the opposite immunosuppressive effect.
Indeed, arginase I plasma levels are upregulated by antiinflam-
matory mediators and downregulated by proinflammatory me-
diators, as shown by correlation analysis. This setting appears to
be decisive in the clinical outcome of cutaneous leishmaniasis—
localized versus metastatic, diffuse disease. The dispersion of
mediators found in the plasma suggests that there are subgroups
of patients with DCL with possible differences in the pattern of
inflammatory response. Since the present study has a limited
number of patients with DCL and therefore subgroup analyzes
would not have statistical significance, further studies are neces-
sary to clarify this question.
In addition to arginase I, ODC, the subsequent downstream
enzyme required for polyamine synthesis, was also enhanced in
plasma specimens from patients with DCL, compared with
those from patients with LCL. In addition to ODC, L-ornithine
Figure 4. Arginase I, ornithine decarboxylase (ODC), and COX-2 expression in lesions biopsy specimens from patients with diffuse cutaneous leishman-
iasis (DCL) and those with localized cutaneous leishmaniasis (LCL). Immunohistochemistry was performed on paraffin-embedded sections of lesion biopsy
specimens from patients with DCL and those with LCL, using primary antibodies against arginase I (2 µg/mL; 1:100), ODC (4 µg/mL; 1:100), and COX-2 (2 µg/
mL; 1:50). The labeling was revealed with diaminobenzidine (DAB), followed by counterstaining with Harris hematoxylin. Data are representative of at least
3 independent assays and were collected in duplicate for each patient. Digital images (400× original magnification) were captured using a Nikon E600
microscope and an Olympus Q-Color 1 digital camera with the Image Pro Plus program. Bars represent 10 µm.
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can also be metabolized to proline by ornithine aminotransfer-
ase, which is related to collagen production. The increased ex-
pression of ODC indicates that the arginase pathway is being
deviated toward the first step of polyamine biosynthesis. In ad-
dition, both arginase I and ODC exhibit increased expression in
DCL lesions, compared with LCL lesions, implying increased
polyamine production in situ. Likewise, we observed positive
correlations between arginase I mRNA levels and the levels of
spermine and spermidine synthase mRNA, the 2 enzymes re-
sponsible for polyamine synthesis. Histological analysis of
DCL lesions revealed heavily parasitized cells, whereas in LCL
lesions, parasites were scarce [13]. Therefore, the high expres-
sion of polyamine biosynthetic enzymes may possibly contrib-
ute to the intense Leishmania proliferation in macrophages in
patients with DCL. However, whether the level of the final prod-
uct polyamine is actually increased in patients with DCL re-
mains unclear and needs to be further investigated.
Arginase I was also related to phospholipase A2, COX-1,
COX-2, and prostaglandin E2 synthase, which are all enzymes
involved in PGE2 syntheses. The relationship between arginase I
and the prostaglandin biosynthetic pathway is reinforced by the
difference in in situ COX-2 expression between DCL and LCL
lesions. COX-2 expression is induced by stimuli such as growth
factors and cytokines. TGF-β has been associated with COX-2/
PGE2 expression in peripheral blood lymphocytes [33], where it
suppresses the degradation of COX-2 mRNA [34]. In addition,
TGF-β enhances arginase activity in macrophages and hence in-
creases polyamine release [35]. In agreement with the literature,
our data demonstrate that both TGF-β and COX-2 are in-
creased in patients with DCL and are positively correlated
with arginase I, suggesting their involvement in its production.
The inhibition of polyamine pathway enzymes is efficient for
experimental Toxoplasma and trypanosome infections [36] and
has been used as a treatment in patients with African sleeping
sickness [37]. Arginase and ODC inhibition directly affects the
production of polyamines, which are critical for the survival
and replication of Leishmania parasites [6, 38]. Hence, in our
model, control of L. amazonensis replication in macrophages
Figure 5. Inhibition of arginase I and ornithine decarboxylase abrogate Leishmania replication in infected human macrophages. Infected macrophage
monolayers were cultured with medium alone (○), NOHA (▾), or DFMO (•) (A). Parasite burden 24 and 72 hours after infection. Each point represents a
different donor, and each bar represents the median. B, Micrographs from Leishmania amazonensis–infected human macrophages unstimulated or in the
presence of 100 mM nor-NOHA or DFMO for 72 hours. Arrows point to amastigotes inside a parasitophorous vacuole. Original magnification × 1000. Bars
represent 10 µm. Differences were evaluated using the Kruskal–Wallis test with the Dunn multiple comparisons post hoc test. Supernatants were collected
after 24 hours and assayed for the presence of transforming growth factor β (TGF-β; C) and prostaglandin E2 (PGE2; D), by enzyme-linked immunosorbent
assay, and the presence of tumor necrosis factor α (TNF-α; E ) and interleukin 12 (IL-12; F ), by the Cytometric Bead Array kit. Statistical significance was
determined by a 2-tailed Mann–Whitney test. Data are representative of at least 3 independent assays and were collected in triplicate for each condition.
Abbreviation: Unst, unstimulated.
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treated with nor-NOHA (arginase inhibitor) and DFMO (ODC
inhibitor) could be mediated by a decrease in polyamine levels.
Furthermore, nor-NOHA and DFMO appear to modulate the in-
flammatory response. Arginase and ODC inhibition decreased
levels of TGF-β and PGE2, which are crucial to parasite survival
and proliferation [39]. Moreover, treatment with nor-NOHA in-
creased levels of TNF-α and IL-12, which can activate macrophag-
es to produce nitric oxide [40], a potent leishmanicidal molecule.
Accordingly, treatment with the arginase inhibitor nor-NOHA al-
tered the cytokine profile, suggesting that the functional status of
macrophages was changed from classical activation to alternative
activation. Interesting, DFMO treatment did not increase proin-
flammatory cytokine production, although DFMO treatment
was as efficient as nor-NOHA in controlling parasite load.
These data suggest that polyamines are sufficient to support
L. amazonensis survival andmultiplication and that the inhibition
of polyamines is decisive for the outcome of infection.
Taken together, our data implicate the local and systemic re-
lease of arginase I, prostaglandins, and polyamines in the inabil-
ity of patients with DCL to mount an efficient immune response
against L. amazonensis infection, providing a favorable envi-
ronment for parasite replication and the dissemination of the
disease. Considering that DCL is still without an effective treat-
ment, the discovery of novel targets for chemotherapy is ex-
tremely important. Our study highlights arginase I, ODC, and
COX-2 as promising targets for DCL treatment, and inhibitors
of these enzymes are already used successfully in the control of
other pathologic conditions. Drugs interfering with these met-
abolic pathways are commercially available and could be used in
future clinical trials, reestablishing a balanced inflammatory re-
sponse to control parasite replication in DCL.
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